S&P Futures
4,034.50 +33.00 (+0.82%) Dow Futures
32,806.00 +218.00 (+0.67%) Nasdaq Futures
12,841.00 +108.50 (+0.85%) Russell 2000 Futures
1,784.30 +19.50 (+1.10%) Crude Oil
73.58 +0.38 (+0.52%) Gold
1,964.40 -9.10 (-0.46%)
eFFECTOR Therapeutics, Inc. (EFTRW)
- GlobeNewswire
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences: Fireside Chat at Cantor’s the Future of Oncology Virtual Symposium on April 3, 2023 at 11am ETFireside Chat at Stifel’s Targeted O
- GlobeNewswire
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Zotatifin continued to demonstrate favorable activity and tolerability, including two previously reported confirmed partial responses (PRs) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A) Enrollment in expanded ECBF+A cohort completed and data is anticipated in first half of 2023 Topline data for Phase 2b KICKSTART trial in NSCLC anticipated in second half of 2023 Cash runway anticipated into first quarter of 2024 SOLANA BEACH and REDWOOD CITY
- GlobeNewswire
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID
Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI)SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced top-line results from its Phase 1b clinical trial of zotatifin for the treatment of COVID demonstrating favorable safety results as well as positive trends in s
